Purpose of review Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in particular, high levels of lowdensity lipoprotein cholesterol (LDL-C) have been associated to a higher cardiovascular risk. Reducing LDL-C levels decreases the risk of coronary heart disease (CHD), and the greater the LDL-C reduction, the greater the decrease in cardiovascular risk. Although statins represent the first line lipid-lowering therapy, many patients do not reach the recommended goals or exhibit adverse side effects leading to therapy discontinuation; in addition, a significant percentage of statin-treated patients continue to experience cardiovascular events even in the presence of well controlled LDL-C levels, because of alterations in other lipid/lipoprotein classes, including triglycerides and high-density lipoprotein cholesterol.
INTRODUCTION
Dyslipidaemias, and in particular hypercholesterolaemia, represent a major risk factor for cardiovascular disease (CVD). Evidence from clinical trials, epidemiological and Mendelian randomization studies has established the causality for low-density lipoprotein cholesterol (LDL-C) and/or triglyceriderich lipoproteins (TGRL) in atherosclerotic CVD [1 && , 2, 3] . Data from meta-analyses of statin trials further proved that reducing LDL-C levels reduces the risk of coronary heart disease (CHD), and that the greater the LDL-C reduction, the greater the decrease in cardiovascular risk [4] [5] [6] [7] .
Despite the established clinical efficacy of statin therapy, several statin-treated patients continue to experience cardiovascular events, even in the presence of well controlled LDL-C levels [8] . This observation suggests that an alteration in the plasma levels of other lipids (such as high triglycerides and/or low HDL-C plasma levels) may confer a residual risk [9, 10] . This may be the case of patients with diabetes, who are characterized by the atherogenic dyslipidaemia (low HDL-C levels, high triglycerides and small dense LDL levels) [11] . A causal association between elevated triglycerides, TGRL or their remnants and increased CVD risk has also been established, independent of LDL-C or HDL-C levels [3, [12] [13] [14] [15] [16] [17] . Statins may affect triglycerides and HDL-C levels: a dose-dependent triglyceride reduction has been reported, ranging from 9 to 25%, with greater reductions observed in patients with higher baseline triglyceride values [18,19 & ]; in addition, all statins are able to increase HDL-C and apoA-I independently of LDL-C reduction but related to the baseline triglyceride levels [20, 21] .
Thus, statins might also represent a reasonable approach for the treatment of patients with increased triglyceride levels and increased cardiovascular risk.
Many patients, however, do not reach the desired goal despite maximal tolerated statin therapy or experience side effects, particularly muscle-related adverse events, when taking statins. The incidence of statin-related side effects is further increased in patients undergoing polytherapy, which increases the probability of drug-drug interactions and the appearance of adverse side-effects [22] . This may lead to therapy discontinuation and makes difficult the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, for whom high doses of high-intensity statins are recommended.
Therefore, although statin therapy represents the first approach in the management of dyslipidaemias, there are patients that require further therapeutic interventions to achieve the recommended lipid goals or patients in whom statins are less effective. This review will focus on three categories of patients that include: statin-intolerant patients, patients not at target and patients with marked hypertriglyceridaemia (HTG).
PATIENTS WITH STATIN INTOLERANCE
Statin intolerance is defined as the inability to tolerate statins, independently on the type and dose [23] . Despite a possible causal association between statin use and myopathy, randomised controlled trials have suggested a small impact of statin therapy on less severe muscle pain (i.e. myalgia) or weakness [24] . In the clinical practice, such symptoms are commonly attributed to statins, as also suggested by the so-called nocebo effect, with an increased rate of muscle-related effects only after having been informed of the statin treatment compared with the blinded use [25 & ]. The occurrence of statinrelated side effects, which appears to be dose-dependent, may lead to therapy discontinuation, and therefore increases the cardiovascular risk of these patients. Thus, the availability of alternative nonstatin lipid-lowering drugs (Fig. 1) , which include bile acid sequestrants, ezetimibe or PCSK9 inhibitors that may be used either as monotherapy or in combination with lower doses of statins (thus, reducing the chance of statin-induced side effects) is essential to reduce the cardiovascular risk of statin-intolerant patients.
Specifically, bile acid sequestrants (cholestyramine, colestipol and more recently colesevelam) act by binding bile acids, thus limiting their reabsorption; indirectly, this results in an increased expression of hepatic LDL receptor (LDLR) and increased LDL catabolism. These drugs reduce LDL-C by 18-25%, with an additional 10-20% reduction whenever added to a statin [26] . This effect translates into a reduction of cardiovascular events, which is proportional to the degree of LDL-C lowering achieved [27, 28] . Bile acid sequestrants may be used also in patients intolerant to statins as well as in those who do not tolerate increasing dose of statins, and may be combined with other lipid-lowering drugs such as ezetimibe, resulting in a greater reduction of LDL-C levels compared with ezetimibe alone [29] .
Ezetimibe reduces intestinal uptake of dietary and biliary cholesterol by inhibiting the interaction with the Niemann-Pick C1-like protein 1 (NPC1L1) [30] . Consequently, the delivery of diet cholesterol to the liver is reduced, thus favouring the increase of hepatic LDLR expression and reducing LDL-C plasma levels. The validity of this approach is confirmed by the fact that NPC1L1-inactivating mutations are associated with lower plasma LDL-C levels and reduced cardiovascular risk [31] . A pooled analysis of over 21 000 patients from 27 clinical trials showed that combining ezetimibe with a statin induces a greater lipid-lowering effect than statin monotherapy [32] . The administration of ezetimibe in combination with low dose of simvastatin (10 mg) for 6 months significantly reduces LDL-C levels and a high percentage of patients achieves the therapeutic target; more importantly, no adverse
KEY POINTS
Despite the clinical efficacy of statin therapy, several patients still need further drugs to reduce their cardiovascular risk.
Statin-intolerant patients require alternative nonstatin therapies to manage their cardiovascular risk, which may include bile acid sequestrants, ezetimibe in combination with low doses of statins, and PCSK9 inhibitors, which seem to represent a valid approach to reduce LDL-C levels and cardiovascular risk.
Specific groups of patients such as those with familial hypercholesterolaemia or with established cardiovascular disease, who are at high cardiovascular risk, often require additional drugs for the management of their cardiovascular risk, which may include PCSK9 inhibitors or ezetimibe in association with a statin.
Patients with severe HTG have an increased cardiovascular risk, and may be treated with fibrates or omega-3 fatty acids, although the final proof of their ability to reduce the cardiovascular risk in these patients is still debated.
Here we discuss the recent findings on newest hypolipidaemic drugs as well as findings from drugs previously used for the management of these specific groups of patients.
events were reported during the study [33] . The effectiveness of this combination in reducing cardiovascular events has been confirmed by several clinical trials [34] [35] [36] . Additional benefits are achieved whenever ezetimibe is combined with atorvastatin or rosuvastatin [37 & ,38 & ,39,40] . Ezetimibe may also be combined with bile acid sequestrants, resulting in an additional reduction of LDL-C levels [29] .
Proprotein convertase subtilisin kexin 9 (PCSK9) is a protein involved in the control of hepatic LDLR expression [41] ; upon binding to the LDLR, it favours its targeting to the lysosome for degradation, thus resulting in a reduced LDLR expression and increased LDL-C levels. Reduced levels or function of PCSK9 are associated with hypocholesterolaemia and reduced cardiovascular risk, suggesting it as a pharmacological target to reduce hypercholesterolaemia [42] . Two fully human monoclonal antibodies against PCSK9, alirocumab and evolocumab, which decrease LDL-C by up to 70%, have been approved for the treatment of patients with primary hypercholesterolaemia not at LDL-C goal despite maximal tolerated lipid-lowering therapy (LLT) as well as for statin-intolerant patients. A number of randomized clinical trials have evaluated the effect of evolocumab in statin-intolerant patients [43,44,45 & ]. The GAUSS-3 study was designed as a two-phase trial to first identify patients with musclerelated adverse events during an atorvastatin rechallenge phase to proceed to the second phase of treatment with evolocumab or ezetimibe [ ]. Similar results were observed whenever alirocumab was compared with ezetimibe in statinintolerant patients: the reduction of LDL-C levels was À45% with alirocumab and À14.6% with ezetimibe (mean treatment difference À30.4%); the incidence of muscle-related adverse events was lower whenever patients had evolocumab compared with the rechallenge phase with atorvastatin [46] . These data indicate a higher effectiveness of anti-PCSK9 mAbs in reducing LDL-C levels compared with ezetimibe in statin-intolerant hypercholesterolaemic patients. Furthermore, the recent data from the FOURIER trial show that inhibition of PCSK9 effectively reduces LDL-C levels and significantly reduces the risk of cardiovascular events [47 && ], suggesting that this therapeutic approach could be effective in reducing the cardiovascular risk of patients intolerant to statins.
HYPERCHOLESTEROLAEMIC PATIENTS NOT AT TARGET DESPITE MAXIMIZED STATIN THERAPY
Despite the established efficacy of statin therapy in reducing LDL-C levels and cardiovascular events, a considerable proportion of patients do not achieve the LDL-C levels recommended by guidelines based on their cardiovascular risk [48 && ]. There are specific groups of patients in whom this proportion is significantly higher, such as patients with familial hypercholesterolaemia or patients with established CVD or very high cardiovascular risk, thus indicating the need of additional LLTs (Fig. 1) . Due to the lifelong exposure to high levels of cholesterol, familial hypercholesterolaemia patients are at high cardiovascular risk; although statin therapy always represents the first approach in these patients, the effectiveness of statins is strictly related to the presence of a functional LDLR, because of the mechanism of action of this class of drugs. Thus, familial hypercholesterolaemia patients on statin therapy are often far from the recommended LDL-C levels [49 & ] and need to be treated with lipidlowering drugs with a mechanism of action differing from that of statins. The addition of ezetimibe to a statin in familial hypercholesterolaemia patients results in an additional 10-15% LDL-C reduction [50] [51] [52] , which may translate into a further reduction of cardiovascular risk. Heterozygous familial hypercholesterolaemia (HeFH) patients are the principle candidates for the therapy with anti-PCSK9 mAbs. Several clinical trials have in fact reported a robust benefit in HeFH patients following the addition of an anti-PCSK9 mAb to their current LLT (maximally tolerated statin with/without other LLT) [53] [54] [55] [56] 57 & ,58,59]. Both alirocumab and evolocumab significantly decrease LDL-C levels by À42.5 up to À67.9% in HeFH under different clinical settings, with higher proportion of patients under anti-PCSK9 mAb therapy reaching the recommended LDL-C levels based on their cardiovascular risk [53] [54] [55] [56] 57 & ,58,59]. The LDL-C lowering effect persists over time and after 78 weeks the LDL-C levels are still significantly low; similarly, the proportion of patients reaching their goal is maintained up to 78 weeks [60 && ]. A pooled analysis of safety data for alirocumab in HeFH patients showed that rates of treatment-emergent adverse events (TEAEs) as well as TEAEs leading to discontinuation are similar in alirocumab and placebo groups [60 && ]. These findings suggest that PCSK9 inhibitors represent a major opportunity for these difficult-to-treat patients to reach the recommended LDL-C levels and, as a consequence, to reduce their high cardiovascular risk.
Patients with established CVD may benefit from the addition of ezetimibe to a statin. As reported by the IMPROVE-IT trial, the addition of ezetimibe to simvastatin not only results in a greater reduction of LDL-C levels compared with simvastatin monotherapy, but also reduces the incidence of cardiovascular events in patients with a recent acute coronary syndrome [34] . The absolute benefit deriving from the combination therapy is small, but significant, thus confirming that lower LDL-C levels always associate with lower cardiovascular risk. Ezetimibe thus represents a second line of therapy that can be added to the current statin therapy to achieve the therapeutic goal; this may be of special relevance in patients at high cardiovascular risk who cannot reach the LDL-C target with the maximal tolerated dose of statins [48 && ]. The FOURIER trial showed that evolocumab added to statin therapy significantly reduced LDL-C levels (mean percentage reduction 59% as compared with placebo) and reduced the risk of cardiovascular events (hazard ratio, 0.85; P < 0.001) in patients with atherosclerotic CVD and LDL-C more than 70 mg/dl (1.81 mmol/l) [47 && ]. A secondary analysis of the FOURIER trial showed that patients who achieved progressively lower LDL-C levels at 4 weeks exhibited progressively a lower rate of cardiovascular events, with adjusted hazard ratios of 0.69 for the primary endpoint and 0.59 for key secondary endpoints in the group with LDL-C less than 10 mg/dl or 0.26 mmol/l at 4 weeks [61 && ]; no serious adverse events or adverse events leading to drug discontinuation were observed in patients achieving such very low LDL-C levels, thus suggesting that lower LDL-C levels (<0.5 mmol/l) can be safely considered for high-risk patients. In addition, evolocumab added to a moderate-intensity or high-intensity statin therapy induced atherosclerotic plaque regression compared with placebo in patients with angiographic coronary disease [62 && ]. Similarly, alirocumab significantly reduced LDL-C plasma levels compared with either placebo (difference À45.9%) or ezetimibe (difference À29.8%) in high-risk patients on maximally tolerated doses of statins; accordingly, a higher proportion of patients on alirocumab achieved the recommended LDL-C levels [63, 64] .
PATIENTS WITH HYPERTRIGLYCERIDAEMIA
For the purpose of this review, we discuss exclusively data about patients with mild-to-moderate HTG (150-880 mg/dl, 1.7-10 mmol/l); we did not include patients with severe HTG (>880 mg/dl, >10 mmol/l), typically associated with a high risk of pancreatitis and determined by monogenic mutations, who require a different therapeutic approach [15] .
Mendelian randomization studies have reported a correlation between both high nonfasting triglyceride levels and remnant cholesterol (i.e. the cholesterol of TGRL) and increased risk of cardiovascular events and all-cause mortality [16, 17] . Despite this, the final evidence of benefits of lowering triglyceride levels are still lacking. To date, no large clinical trials addressing specific clinical outcomes have been www.co-lipidology.comcompleted in which patients were recruited based on their elevated levels of triglycerides or TGRL, and thus, the evidence to support triglyceride-lowering therapies is less robust than for LDL-C. Thus, although clinical trials investigating the effects of triglyceride-lowering drugs on cardiovascular outcomes have reported conflicting results, a recent meta-analysis reported an overall modest cardiovascular risk reduction (12%), which, however, was more consistent in specific patient subgroups, such as those with high triglycerides (18% risk reduction) and even more in patients with high triglycerides and low HDL-C (29% risk reduction) [65 & ].
In addition to these considerations, it is worth noting that many patients treated with statins still exhibit high levels of non-HDL-C, which reflects an increase in triglyceride-rich lipoprotein cholesterol [66, 67] , suggesting the need of additional therapies able to lower specifically triglyceride levels. The available pharmacological interventions that substantially reduce triglycerides and triglyceride-rich lipoprotein cholesterol include fibrates and n-3 PUFAs.
Fibrates are agonists of peroxisome proliferatoractivated receptor-a (PPAR-a), which act by regulating various steps in lipid and lipoprotein metabolism, resulting in reduced fasting triglyceride levels, postprandial triglycerides and triglyceride-rich lipoprotein remnant particles. Contrasting results have been reported from meta-analyses of fibrates in clinical trials; in fact, although some meta-analyses did not observe any cardiovascular benefit [68, 69] , others reported a reduction of cardiovascular events in specific group of patients with high triglyceride levels associated with low HDL-C [70] [71] [72] . Thus, although overall these results may be suggestive of a clinical benefit in subgroups of high cardiovascular risk patients, specific clinical trials are essential to substantiate this hypothesis. The novel selective PPARa modulator pemafibrate is currently under investigation in patients with diabetes to evaluate the effect of triglyceride lowering on cardiovascular outcomes (PROMINENT, NCT03071692). N-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] efficiently reduce triglyceride levels by several mechanisms [73] . The recommended doses of EPA with DHA is 2-4 g/day, which translate into a 25-30% reduction of triglyceride levels [73] . Whether this relevant reduction of plasma triglyceride levels may also translate into a clinical benefit is still debated. In fact, although some studies reported significant reduction of cardiovascular outcomes following the treatment with omega-3 fatty acids [74, 75] , other studies failed to observe any kind of protection [76] . A large systematic review including data from 20 clinical trials reported that omega-3 fatty acids protected against vascular death (RR ¼ 0.96, P ¼ 0.03) but overall there was no effect on composite cardiovascular events (RR ¼ 0.96, P ¼ 0.24) [77] . Two ongoing randomized placebocontrolled trials (REDUCE-IT, NCT01492361 and STRENGTH, NCT02104817) are evaluating the effect of omega-3 fatty acids on CVD outcomes in patients with high triglyceride levels.
CONCLUSION
The reduction of LDL cholesterol is one of the pillars in the prevention of CVD. Statins are the first line therapy as suggested by the major guidelines and the benefit is directly proportional to the absolute LDL-C level decrease and the absolute cardiovascular risk of the patient. Yet there are circumstances under which either the hypolipidaemic response is deemed as insufficient (especially in patients with the so-called statin intolerance) or patients are affected of other forms of dyslipidaemia that confer additional cardiovascular risk. The size of these populations varies widely from survey to survey but certainly account for a relatively large part of the high and very high-risk population and other nonstatin treatments represent a powerful tool in the armamentarium of the physician to provide the best cardiovascular protection possible. 
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